西藏易明西雅医药科技股份有限公司 关于确认公司董事、监事和高级管理人员 2024 年度薪酬的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）第三届董事会第 二十三次会议审议了《关于确认公司董事、高级管理人员 2024 年度薪酬的议案》， 以及第三届监事会第二十一次会议审议了《关于确认公司监事 2024 年度薪酬的 议案》，全体董事、监事回避表决，上述议案尚需提交公司 2024 年年度股东大 会审议，现将相关事项公告如下： 证券代码：002826 证券简称：易明医药 公告编号：2025-024 三、备查文件 1、第三届董事会第二十三次会议决议； 1 特此公告。 一、公司董事、监事和高级管理人员 2024 年度薪酬情况 2024 年度，在公司任职的非独立董事、监事和高级管理人员根据其在公司 或子公司担任的职务，按公司相关薪酬规定领取薪金。独立董事的薪酬为每年 20 万元按月发放。公司董事、监事和高级管理人员 2024 年度薪酬情况详见《公 司 2024 年年度报告》相应章节披露内容。 二、其他事项 1、上 ...

| 序号 | 召开时间 | | 届次 | 会议审议通过议案 | | --- | --- | --- | --- | --- | | | | | | 8.《关于公司<续聘 2024 年会计师事务所>的议案》 | | | | | | 9.《关于使用自有资金进行现金管理的议案》 | | | | | | 10《关于修订 . <公司章程>、修订和新增公司部分治 | | | | | | 理制度的议案》 | | | | | | 11《关于修订公司部分基本管理制度及内控制度的 . | | | | | | 议案》 | | | | | | 12.《关于提请股东大会授权董事会办理以简易程 | | | | | | 序向特定对象发行股票的议案》 | | | | | | 13.《关于公司<2024 年第一季度报告>的议案》 | | 2 | 2024 年 8 月 | 14 日 | 第三届监事会 | 1.《关于公司 2024 年半年度报告及其摘要的议 | | | | | 第十六次会议 | 案》 | | | | | 第三届监事会 | | | 3 | 年 月 2024 9 | 日 10 | 第十七次临时 | 1.《关于对参股公司减资暨关联交易的 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-020 西藏易明西雅医药科技股份有限公司 关于内蒙古博斯泰企业管理服务有限公司业绩承诺实现 情况说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于2025年4月23 日召开第三届董事会第二十三次会议，审议通过了《关于内蒙古博斯泰企业管 理服务有限公司业绩承诺实现情况说明的议案》，现将具体情况公告如下： 一、交易概述 公司于2021年8月13日召开第二届董事会第二十次会议，审议通过了《关于 公司收购内蒙古博斯泰企业管理服务有限公司51%股权的议案》，公司以支付现 金的方式收购内蒙古博斯泰企业管理服务有限公司（以下简称"博斯泰"）股 东王键泽先生持有的该公司51%股权，交易价格为人民币3,060.00万元，双方签 订了《股权转让协议》。博斯泰于2021年9月2日完成工商变更登记工作。 具体内容详见公司在《证券时报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）上于2021年8月14日登载的《关于公司收购内蒙古博斯 泰企 ...

西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025年4月23 日召开第三届董事会第二十三次会议审议通过了《关于修订<公司章程>的议案》， 本议案尚需提交公司股东大会审议。 为贯彻落实新《公司法》，进一步提升上市公司规范运作水平，中国证券监 督管理委员会于2025年3月28日发布了新的《上市公司章程指引》，公司结合《公 司法》《证券法》《上市公司章程指引》和其他有关规定对《公司章程》进行了 修改，完善总则、法定代表人、股份发行等规定；完善股东、股东会相关制度； 完善董事、董事会及专门委员会的要求。 证券代码：002826 证券简称：易明医药 公告编号：2025-021 西藏易明西雅医药科技股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 修订具体情况如下： | 原条款 | 修订后的条款 | | --- | --- | | 全文"股东大会" | "股东会" | | 第一章 总则 | | | 第一条 为维护西藏易明西雅医药科技股份有限 | 第一条 为维护西藏易明西雅医药科技股份有限 | | 公司（以下称"公司"） ...

西藏易明西雅医药科技股份有限公司董事会 关于2024年会计师事务所履职情况评估报告 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）聘 请立信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"或"立 信"）为公司2024年度财务报告审计机构和内部控制审计机构。 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上 市公司选聘会计师事务所管理办法》和《公司章程》等有关规定和要求，本公司 对立信会计师事务所的履职情况进行了评估。经评估，公司认为立信会计师事务 所具备执业资质，履职能够保持独立性，勤勉尽责，公允表达意见。具体情况如 下： 一、资质条件 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业务 许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB）注 册登记。 截至 2024 年末，立信拥有合伙人 ...

西藏易明西雅医药科技股份有限公司 2024 年度财务决算报告 2024 年公司在董事会决策和经理层的领导下，在公司经营班子及全体员工的共 同努力下，2024 年度实现归属于上市公司股东的净利润 45,928,802.86 元。现将公 司 2024 年度财务决算情况报告如下： 西藏易明西雅医药科技股份有限公司 2024 年度财务决算报告 一、会计报表审计意见 公司 2024 年度财务报告经立信会计师事务所（特殊普通合伙）审计，出具了信 会师报字[2025]第 ZA11581 号标准无保留意见的审计报告。立信会计师事务所认为 易明医药财务报表在所有重大方面按照企业会计准则的规定编制，公允反映易明医 药 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营 成果和现金流量。 二、财务数据和指标 | 项目 | 2024 年 | 2023 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业收入（元） | 651,883,906.60 | 667,038,998.92 | -2.27% | | 归属于上市公司股东的净利润 | 45,928,80 ...

西藏易明西雅医药科技股份有限公司 审计委员会对会计师事务所2024年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》和《公司章程》等规定 和要求，西藏易明西雅医药科技股份有限公司（以下简称"公司"）董事会审计 委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会 计师事务所 2024 年度履职评估及履行监督职责的情况报告如下 一、2024年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业务 许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB）注 册登记。 截至 2024 年末，立信拥有合伙人 29 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥148,531,481.16, a decrease of 7.41% compared to ¥160,425,522.45 in the same period last year[4]. - Net profit attributable to shareholders was ¥18,793,851.93, down 32.64% from ¥27,899,079.55 year-on-year[4]. - The basic earnings per share decreased by 33.33% to ¥0.10 from ¥0.15 in the same period last year[5]. - Net profit for the period was CNY 18,928,556.57, down 32.5% from CNY 28,050,728.06 in the previous period[27]. - The net profit attributable to the parent company was 18,793,851.93, a decrease from 27,899,079.55, representing a decline of approximately 32.7% year-over-year[28]. - The total comprehensive income attributable to the parent company was 18,727,675.15, down from 27,944,608.45, indicating a decrease of about 32.9% compared to the previous period[28]. Cash Flow and Operating Activities - Cash flow from operating activities decreased by 42.56% to ¥30,865,875.72 from ¥53,738,523.14 in the same period last year[10]. - Net cash flow from operating activities decreased by 42.56% year-on-year, primarily due to a decrease of CNY 18.185 million in special industrial support funds received[11]. - Cash inflows from operating activities totaled 190,986,029.02, compared to 202,042,040.04 in the previous period, showing a decrease of approximately 5.5%[29]. - The net cash flow from operating activities was 30,865,875.72, down from 53,738,523.14, representing a decline of about 42.6% year-over-year[30]. - The company received cash from sales of goods and services amounting to 178,926,631.19, an increase from 170,015,189.63, reflecting a growth of about 5.3%[29]. - The company paid 38,337,179.15 in cash for goods and services, down from 41,711,034.09, indicating a decrease of approximately 8.5%[30]. - The company reported a cash outflow of 79,324,691.65 for other operating activities, which increased from 60,947,936.52, representing a rise of about 30.0%[30]. Assets and Liabilities - The company's total assets increased by 6.48% to ¥986,510,989.35 from ¥926,469,234.87 at the end of the previous year[5]. - Total assets increased to CNY 986,510,989.35 from CNY 926,469,234.87, representing a growth of 6.5%[24]. - Total liabilities rose to CNY 218,975,807.44 from CNY 180,892,906.43, an increase of 21.1%[25]. - The company's equity attributable to shareholders increased to CNY 760,827,826.19 from CNY 739,003,677.36, a rise of 2.9%[25]. Research and Development - Research and development expenses rose by 342.13% to ¥1,197,352.52 from ¥270,814.38 year-on-year[10]. - R&D expenses increased by CNY 926,500 compared to the same period last year, primarily due to increased investment in research and development[11]. - Research and development expenses increased to CNY 1,197,352.52 from CNY 270,814.38, a significant increase of 341.5%[27]. Financial Management and Investments - The company reported a significant increase in short-term borrowings by 54.69%, amounting to ¥35,300,443.10 compared to ¥22,819,445.17 previously[9]. - The company received government subsidies amounting to ¥10,223,089.90, primarily related to industry support funds[7]. - Financial expenses increased by CNY 592,900 compared to the same period last year, mainly due to a decrease in interest income from current deposits[11]. - Investment income increased by CNY 228,100 compared to the same period last year, mainly due to increased income from financial product investments[11]. - The company has entrusted CNY 20 million in financial management, with all funds remaining unexpired[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,855[13]. - The largest shareholder, Gao Fan, holds 25.59% of the shares, totaling 48,800,382 shares[13]. - The company completed the first grant registration of the 2024 restricted stock incentive plan, granting 3.44 million shares at a price of CNY 6.45 per share[16].

证券代码：002826 股票简称：易明医药 公告编号：2025-026 西藏易明西雅医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"本公司"或"公司"）第 三届董事会第二十三次会议审议通过了《关于召开 2024 年年度股东大会的议案》， 定于 2025 年 5 月 16 日（星期五）下午 14:00 召开 2024 年年度股东大会，现将 本次会议的相关事项通知如下： 一、本次会议召开的基本情况 （一）会议届次：2024 年年度股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法、合规性：公司第三届董事会第二十三次会议审议通 过相关议案，本次股东大会会议的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》等的规定。 （四）会议表决方式：现场记名书面投票与网络投票相结合 （五）会议时间： 1、现场会议时间为：2025 年 5 月 16 日（星期五）下午 14:00。 2、网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 16 日上午 9 ...

Financial Performance - The company's operating revenue for 2024 was CNY 651,883,906.60, a decrease of 2.27% compared to CNY 667,038,998.92 in 2023[17] - Net profit attributable to shareholders for 2024 reached CNY 45,928,802.86, representing a significant increase of 198.50% from CNY 15,386,479.71 in 2023[17] - The net profit after deducting non-recurring gains and losses was CNY 18,446,708.96, up 1,579.33% from CNY 1,098,456.92 in the previous year[17] - The net cash flow from operating activities was CNY 111,572,566.21, down 33.14% from CNY 166,880,943.95 in 2023[17] - Basic earnings per share for 2024 were CNY 0.25, an increase of 212.50% compared to CNY 0.08 in 2023[17] - Total assets at the end of 2024 were CNY 926,469,234.87, a slight decrease of 0.14% from CNY 927,743,602.85 at the end of 2023[17] - Net assets attributable to shareholders decreased by 0.81% to CNY 739,003,677.36 from CNY 745,017,765.57 in 2023[17] - The weighted average return on net assets for 2024 was 6.26%, an increase of 4.19% from 2.07% in 2023[17] Revenue and Profit Trends - The company's total revenue for Q1 was approximately ¥160.43 million, with a decline to ¥139.04 million in Q4, reflecting a decrease of about 13.4% quarter-over-quarter[21] - Net profit attributable to shareholders decreased significantly from ¥27.90 million in Q1 to ¥4.11 million in Q4, indicating a decline of approximately 85.3%[21] - Cardiovascular product revenue decreased by 55.61% to ¥84,210,323.29, while diabetes product revenue increased by 41.17% to ¥474,057,188.28[56] Cash Flow and Investments - The cash flow from operating activities showed volatility, with a net cash inflow of ¥67.71 million in Q3, but a net outflow of ¥2.26 million in Q4[21] - Investment cash inflow increased by 15.24% to ¥521,239,418.32, while investment cash outflow rose by 1.40% to ¥502,242,767.81, leading to a net cash flow from investment activities of ¥18,996,650.51, a significant turnaround from a negative cash flow in the previous year[77] - Financing cash inflow surged by 107.27% to ¥22,799,206.96, while financing cash outflow decreased by 4.61% to ¥67,062,215.78, resulting in a net cash flow from financing activities of -¥44,263,008.82, an improvement of 25.36% compared to the previous year[78] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1 per 10 shares to all shareholders, based on a total of 186,913,950 shares[3] - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares (including tax), with a total cash dividend amounting to RMB 18,691,395.00[153] - The cash dividend distribution accounts for 100% of the total profit distribution amount[153] Market Position and Product Development - The core product, Miglitol tablets (Aotianping®), holds the largest market share in China's Miglitol formulation market, with successful bids in 25 provinces as of the reporting period[38] - The company has developed a diverse business model, including self-produced drugs, third-party cooperative drugs, raw materials, and drug promotion services[38] - The company’s self-produced drugs are all included in the 2024 National Medical Insurance Directory, indicating strong market competitiveness and growth potential[44] - The company is committed to continuous innovation and development in the pharmaceutical sector, focusing on chronic disease treatments and gynecological core products[37] Research and Development - R&D expenses rose by 12.92% to ¥15,482,858.58, indicating a focus on innovation and product development[69] - The number of R&D personnel increased by 14.63% from 41 in 2023 to 47 in 2024, with the proportion of R&D staff rising from 9.34% to 11.66%[75] - R&D investment amounted to ¥15,982,858.58 in 2024, representing a 32.36% increase from ¥12,075,151.59 in 2023, with R&D investment as a percentage of operating revenue rising from 1.81% to 2.45%[75] Compliance and Governance - The company has maintained compliance with industry regulations, enhancing its operational integrity and market competitiveness[33] - The company is enhancing its governance structure and management level to ensure effective operation as its scale increases[99] - The company operates independently from its controlling shareholders in terms of business, finance, personnel, and assets, ensuring no major related party transactions[117] Environmental Responsibility - The company has been recognized as an environmentally friendly enterprise by the Sichuan Provincial Department of Ecology and Environment, maintaining compliance with environmental regulations[52] - The company has invested a total of 712,700 yuan in environmental governance and protection in 2024, including an environmental protection tax of 290 yuan[170] - The company has established an environmental self-monitoring plan for 2024, including quarterly and monthly monitoring of wastewater and air emissions[169] Employee and Management Structure - The total number of employees at the end of the reporting period is 403, with 135 in production, 98 in sales, and 54 in technical roles[148] - The company has implemented a performance-based salary system that includes basic salary, performance salary, and benefits[149] - The company has conducted various training programs for employees, including management training and new employee onboarding[152] Investor Relations and Transparency - The company is actively engaging with investors through various communication channels to enhance transparency and information sharing[110] - The company has established a talent strategy, focusing on employee rights and providing various training opportunities for continuous growth[172] - The company has maintained a strong commitment to information disclosure, ensuring timely and accurate updates on its financial status and major events[174]